title: Treatment of congestive heart failure and Cheyne-Stokes respiration during sleep by continuous positive airway pressure.
abstract: A previous uncontrolled study suggested that nasal continuous positive airway positive airway pressure (NCPAP) may improve left ventricular ejection fraction (LVEF) in patients with congestive heart failure (CHF) and Cheyne-Stokes respiration with central sleep apnea (CSR-CSA). In order to more critically evaluate the effects of NCPAP on cardiac function, we undertook a randomized, controlled trial of NCPAP in 29 patients with heart failure and CSR-CSA over a 3-mo period, with LVEF as the primary outcome measure. Patients with CHF and associated CSR-CSA who were receiving optimal medical therapy were randomly assigned to a control group (n = 15) or a group receiving nightly NCPAP (n = 14). Twelve patients in each group completed the study. There was a greater improvement of LVEF in the NCPAP group than in the control group during the study (mean +/- SEM = 7.7 +/- 2.5 versus - 0.5 +/- 1.5%, p = 0.019). In addition, there was a significantly greater reduction in the number of apneas and hypopneas (-28.5 +/- 3.9 versus -6.1 +/- 7.0 per hour of sleep, p = 0.012) in the NCPAP group than in the control group. Significantly greater improvements in symptoms of fatigue (5.6 +/- 1.2 versus 0.8 +/- 0.7, p = 0.005) and disease mastery (3.6 +/- 1.1 versus -0.7 +/- 0.7, p = 0.031) were also observed in the NCPAP group. We conclude that in patients with chronic heart failure and CSR-CSA, nightly administration of NCPAP can attenuate CSR-CSA, improve cardiac function, and alleviate symptoms of heart failure.
authors: Sleep Research Laboratory, Queen Elizabeth Hospital, Toronto, Ontario, Canada.
authors: M T
authors: MT
authors: Naughton
authors: P P
authors: PP
authors: Liu
authors: D C
authors: DC
authors: Bernard
authors: R S
authors: RS
authors: Goldstein
authors: T D
authors: TD
authors: Bradley
mesh_terms: D000704:Analysis of Variance; D002639:Cheyne-Stokes Respiration / Q000503:physiopathology / Q000628:therapy*; D006333:Heart Failure / Q000503:physiopathology / Q000628:therapy*; D006801:Humans; D016018:Least-Squares Analysis; D008875:Middle Aged; D009666:Nose; D017286:Polysomnography; D011175:Positive-Pressure Respiration / Q000009:adverse effects / Q000379:methods / Q000706:statistics & numerical data; D011788:Quality of Life; D012893:Sleep Wake Disorders / Q000503:physiopathology / Q000628:therapy*; D013318:Stroke Volume